don't disagree that it's attractive. but you're assuming management can actually deliver. There have been a few failures in the past - i.e. Ultralute that was supposed to be a new product but shelved.
Not saying it isn't attractive, but at close to US$300m market cap off less than $5m of profit even after adding back FDA expenses it's not quite as cheap as it once was - you have to believe in the vision to buy at these prices
Ann: SNMMI Announcement Regarding USFDA Approval of Technegas, page-3
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
91.0¢ |
Change
-0.040(4.21%) |
Mkt cap ! $101.1M | |||
| Open | High | Low | Value | Volume |
| 95.0¢ | 97.0¢ | 90.0¢ | $177.9K | 194.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1210 | 91.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 92.0¢ | 1661 | 1 |
View Market Depth
| Last trade - 16.10pm 26/06/2025 (20 minute delay) ? |
| CYC (ASX) Chart |